IE892640L - Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders - Google Patents

Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders

Info

Publication number
IE892640L
IE892640L IE892640A IE264089A IE892640L IE 892640 L IE892640 L IE 892640L IE 892640 A IE892640 A IE 892640A IE 264089 A IE264089 A IE 264089A IE 892640 L IE892640 L IE 892640L
Authority
IE
Ireland
Prior art keywords
defective
genomes
packaging
hepadnavirus
hepadnaviruses
Prior art date
Application number
IE892640A
Original Assignee
Tate & Lyle Plc
Biotest Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tate & Lyle Plc, Biotest Pharma Gmbh filed Critical Tate & Lyle Plc
Publication of IE892640L publication Critical patent/IE892640L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to replication-defective hepadnaviruses. In particular, the invention relates to two types of defective hepadnavirus genomes, and the nucleic acid sequences thereof. The first type (termed herein ''particle-defective''genomes) are incapable of supplying all hepadnaviral functions required for replication, but are able to produce a pregenomic RNA with the appropriate cis-acting signals necessary for inclusion of the RNA in virions (packaging) and for reverse transcription into DNA. The second type of defective hepadnavirus genomes of the invention, termed herein ''packaging genomes'', produced pregenomic RNA which cannot be packaged and/or reverse-transcribed into a double-stranded genomic DNA, and produce messenger RNAs capable of supplying functions required in trans for packaging. The present invention also relates to therapeutic uses of both hepadnavirus packaging genome products and virion particles consisting of packaged particle-defective genomes such as the prevention of hepadnavirus infection or its sequelae and for purposes of gene therapy. [WO9002176A1]
IE892640A 1988-08-16 1989-08-16 Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders IE892640L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23281188A 1988-08-16 1988-08-16

Publications (1)

Publication Number Publication Date
IE892640L true IE892640L (en) 1990-02-16

Family

ID=22874695

Family Applications (1)

Application Number Title Priority Date Filing Date
IE892640A IE892640L (en) 1988-08-16 1989-08-16 Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders

Country Status (8)

Country Link
EP (1) EP0380656A1 (en)
AU (1) AU4315689A (en)
DK (1) DK93390A (en)
FI (1) FI901876A0 (en)
IE (1) IE892640L (en)
IL (1) IL91335A0 (en)
WO (1) WO1990002176A1 (en)
ZA (1) ZA896246B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2091928T3 (en) * 1990-04-20 1996-11-16 Gen Hospital Corp PREVENTION METHODS FOR VIRAL REPLICATION.
US5610050A (en) * 1990-04-20 1997-03-11 The General Hospital Corporation Methods of preventing viral replication
FR2716459B1 (en) * 1994-02-22 1996-05-10 Univ Paris Curie Host-vector system usable in gene therapy.
US5869248A (en) * 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US5683873A (en) * 1995-01-13 1997-11-04 Innovir Laboratories, Inc. EGS-mediated inactivation of target RNA
US6057153A (en) * 1995-01-13 2000-05-02 Yale University Stabilized external guide sequences
DE19517532C2 (en) * 1995-05-12 1999-10-28 Max Planck Gesellschaft HBV vectors and cells for their delivery
US5980901A (en) * 1996-09-18 1999-11-09 The Board Of Regents Of The University Of Texas System Viral defective interfering particles and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861588A (en) * 1985-02-05 1989-08-29 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers

Also Published As

Publication number Publication date
IL91335A0 (en) 1990-03-19
FI901876A7 (en) 1990-04-12
DK93390A (en) 1990-06-15
AU4315689A (en) 1990-03-23
ZA896246B (en) 1990-06-27
EP0380656A1 (en) 1990-08-08
DK93390D0 (en) 1990-04-11
FI901876A0 (en) 1990-04-12
WO1990002176A1 (en) 1990-03-08

Similar Documents

Publication Publication Date Title
Gruss et al. Splicing as a requirement for biogenesis of functional 16S mRNA of simian virus 40.
Elias et al. A DNA binding protein specific for an origin of replication of herpes simplex virus type 1.
Huang Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid
Casey Control of ADAR1 editing of hepatitis delta virus RNAs
EP3307894B1 (en) Non-integrating viral delivery system and methods of use thereof
Bhat et al. Adenovirus mutants with DNA sequence perturbations in the intragenic promoter of VAI RNA gene allow the enhanced transcription of VAII RNA gene in HeLa cells
AU662304B2 (en) DNA construct for providing RNA therapy
Mensa-Wilmot et al. Reconstitution of a nine-protein system that initiates bacteriophage λ DNA replication
Calvert et al. Two regions of an avian hepadnavirus RNA pregenome are required in cis for encapsidation
JP2003527856A5 (en)
WO1987007300A3 (en) Inhibition of htlv-iii by exogenous oligonucleotides
WO2002079186A3 (en) Aminopiperidine derivatives as modulators of chemokine receptor activity
Bean Jr et al. Transcriptase activity and genome composition of defective influenza virus
IE892640L (en) Defective hepadnaviruses and producer cell line for vaccines¹and treatment of liver diseases and disorders
Baglioni et al. Cleavage of nascent reovirus mRNA by localized activation of the 2'-5'-oligoadenylate-dependent endoribonuclease
Giantini et al. Reovirus type 3 genome segment S4: nucleotide sequence of the gene encoding a major virion surface protein
Taylor Hepatitis delta virus
Cherrington et al. Upstream sequences and cap proximity in the regulation of polyadenylation in ground squirrel hepatitis virus
Muto et al. Inhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA construct
Hodge et al. Effects of mutations within the herpes simplex virus type 1 DNA encapsidation signal on packaging efficiency
Jenson et al. Sequences of the Epstein-Barr virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA
Netter et al. Nucleotide sequence stability of the genome of hepatitis delta virus
EP0528903B1 (en) Methods of preventing viral replication
Srivastava Inhibition of oncorna virus and cellular DNA polymerases by natural and synthetic polynucleotides
IL124636A (en) Conditionally replicating viral vectors and their use